IGF-I treatment reduces hyperphagia, obesity, and hypertension in metabolic disorders induced by fetal programming

Endocrinology

Volumn 142, Issue 9, 2001, Pages 3964-3973

  Vickers, Mark H ^a   Ikenasio, Bettina A ^a   Breier, Bernhard H ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEPTIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; FEMALE; FOOD INTAKE; HYPERINSULINEMIA; HYPERPHAGIA; HYPERTENSION; INSULIN BLOOD LEVEL; MALNUTRITION; MATERNAL NUTRITION; METABOLIC DISORDER; MINIPUMP; NONHUMAN; OBESITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RAT; RISK FACTOR; SYNDROME X; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

EID: 0034877472     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.9.8390     Document Type: Article

References (66)

1. Fetal nutrition and adult disease
2. Long-term consequences of intrauterine growth retardation
3. The fetal and infant origins of disease
4. Fetal origins of hyperphagia, obesity and hypertension and its postnatal amplification by hypercaloric nutrition
5. A model of intrauterine growth retardation caused by chronic maternal undernutrition in the rat: Effects on the somatotropic axis and postnatal growth
6. Chronic maternal undernutrition in the rat leads to delayed postnatal growth and elevated blood pressure of offspring
7. Role of insulin resistance in human disease (syndrome X): An expanded definition
8. Insulin signaling and action in fat cells: Associations with insulin resistance and type 2 diabetes
9. Nutritional influences in early life upon obesity and body proportions
10. Obesity at the age of 50 y in men and women exposed to famine prenatally
11. Intrauterine food restriction is associated with obesity in young rats
12. Maternal hormonal manipulations in rats cause obesity and increase medial hypothalamic norepinephrine release in male offspring
13. Role of insulin-like growth factors in embryonic and postnatal growth
14. IGF-I is required for normal embryonic growth in mice
15. Postnatal catch-up growth induced by growth hormone and insulin-like growth factor-I in rats with intrauterine growth retardation caused by maternal protein malnutrition
16. Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance
17. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
18. Leptin is suppressed during infusion of recombinant human insulin-like growth factor I (rhIGF I) in normal rats
19. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus
20. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure
21. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I
22. Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice
23. IGF-I treatment attenuates renal abnormalities induced by neonatal ACE inhibition
24. Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders
25. Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) and hepatic mRNA are increased in the small for gestational age (SGA) fetal rat
26. Maternal hypoxia as a model for intrauterine growth retardation: Effects on insulin-like growth factors and their binding proteins
27. Radioimmunoassays for IGFs and IGFBPs
28. Growth hormone (GH) therapy markedly increases the motility of spermatozoa and the concentration of insulin-like growth factor-I in seminal vesicle fluid in the male GH-deficient dwarf rat
29. Analysis of serum insulin-like growth factor binding proteins using Western-ligand blotting: Use of the method for titration of the binding proteins and competitive binding studies
30. Ontogenic differences in the nutritional regulation of circulating IGF binding proteins in sheep plasma
31. Administration of growth hormone (GH), but not insulin-like growth factor-I (1GF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats
32. Dysregulation of the adipoinsular axis may be an important determinant for the development of hyperphagia, obesity and type 2 diabetes during adult life
33. Responses of young energy-restricted sheep to chronically administered insulin-like growth factor I (IGF-I): Evidence that IGF-I suppresses the hepatic growth hormone receptor
34. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro
35. Short- and long-term metabolic effects of recombinant human 1GF-I treatment in patients with severe insulin resistance and diabetes mellitus
36. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats
37. Insulin-like growth factors: A role in growth hormone negative feedback and body weight regulation via brain
38. Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats
39. Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomised rats
40. Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects
41. Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle
42. Metabolic effects of insulin-like growth factor-I: A focus on insulin sensitivity
43. Regulation of leptin production in cultured mature white adipocytes
44. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line
45. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus
46. The adipoinsular axis: Effects of leptin on pancreatic β-cells
47. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B
48. Direct effect of insulin and insulin-like growth factor-I on the secretory activity of rat pancreatic β cells
49. Perspective: The insulin signaling system - A common link in the pathogenesis of type 2 diabetes
50. Glucose and insulin metabolism in hypertension
51. Altered ionic effects of insulin in hypertension: Role of basal ion levels in determining cellular responsiveness
52. Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders
53. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis
54. The role of the GH/IGF-I axis for cardiac function and structure
55. Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP superfamily
56. Changes in IGF-I and -II, IGF binding protein, and IGF receptor transcript abundance after uterine artery ligation
57. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy
58. Effect of insulin on the hepatic production of insulin- like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes
59. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus
60. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in plasma of growth-hormone-deficient rats
61. Insulin and insulin-like growth factor-1 regulate hepatic insulin-like growth factor binding protein-3 by different mechanisms
62. The insulin-like growth factors and their binding proteins
63. Insulin-like growth factors and their binding proteins: Biological actions
64. Evidence for a novel insulin-like growth factor (IGF)-dependent protease regulating IGF-binding protein-4 in dermal fibroblasts
65. Insulin-like growth factors (IGFs) reduce IGF-binding protein-4 (IGFBP-4) concentration and stimulate IGFBP-3 independently of IGF receptors in human fibroblasts and epidermal cells
66. Regulation of IGFBP-4 levels in human intestinal muscle by an IGF-I-activated, confluence-dependent protease